603259 Stock Overview
An investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
WuXi AppTec Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥49.63 |
| 52 Week High | CN¥85.12 |
| 52 Week Low | CN¥36.36 |
| Beta | 0.81 |
| 11 Month Change | -6.36% |
| 3 Month Change | 30.13% |
| 1 Year Change | -40.75% |
| 33 Year Change | -64.46% |
| 5 Year Change | -5.24% |
| Change since IPO | 275.34% |
Recent News & Updates
An Intrinsic Calculation For WuXi AppTec Co., Ltd. (SHSE:603259) Suggests It's 47% Undervalued
Nov 13
Is WuXi AppTec Co., Ltd. (SHSE:603259) Potentially Undervalued?
Oct 22WuXi AppTec Co., Ltd. (SHSE:603259) Stock Catapults 34% Though Its Price And Business Still Lag The Market
Oct 01Recent updates
An Intrinsic Calculation For WuXi AppTec Co., Ltd. (SHSE:603259) Suggests It's 47% Undervalued
Nov 13Is WuXi AppTec Co., Ltd. (SHSE:603259) Potentially Undervalued?
Oct 22WuXi AppTec Co., Ltd. (SHSE:603259) Stock Catapults 34% Though Its Price And Business Still Lag The Market
Oct 01Benign Growth For WuXi AppTec Co., Ltd. (SHSE:603259) Underpins Its Share Price
Jul 30These 4 Measures Indicate That WuXi AppTec (SHSE:603259) Is Using Debt Reasonably Well
Jul 12WuXi AppTec (SHSE:603259) Has Announced That It Will Be Increasing Its Dividend To CN¥0.9897
Jun 23We Think Some Shareholders May Hesitate To Increase WuXi AppTec Co., Ltd.'s (SHSE:603259) CEO Compensation
Jun 05WuXi AppTec (SHSE:603259) Has A Pretty Healthy Balance Sheet
Apr 09WuXi AppTec Co., Ltd. (SHSE:603259) Analysts Just Slashed This Year's Estimates
Mar 23Benign Growth For WuXi AppTec Co., Ltd. (SHSE:603259) Underpins Its Share Price
Mar 01Shareholder Returns
| 603259 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -6.1% | -4.4% | -2.1% |
| 1Y | -40.7% | -32.3% | 2.8% |
Return vs Industry: 603259 underperformed the CN Life Sciences industry which returned -32.3% over the past year.
Return vs Market: 603259 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 603259 volatility | |
|---|---|
| 603259 Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 10.6% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603259 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603259's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 38,134 | Ge Li | www.wuxiapptec.com |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
WuXi AppTec Co., Ltd. Fundamentals Summary
| 603259 fundamental statistics | |
|---|---|
| Market cap | CN¥140.71b |
| Earnings (TTM) | CN¥8.06b |
| Revenue (TTM) | CN¥38.50b |
17.8x
P/E Ratio3.7x
P/S RatioIs 603259 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603259 income statement (TTM) | |
|---|---|
| Revenue | CN¥38.50b |
| Cost of Revenue | CN¥22.86b |
| Gross Profit | CN¥15.64b |
| Other Expenses | CN¥7.57b |
| Earnings | CN¥8.06b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.79 |
| Gross Margin | 40.61% |
| Net Profit Margin | 20.94% |
| Debt/Equity Ratio | 10.1% |
How did 603259 perform over the long term?
See historical performance and comparison